About Partners Intelligence Log in →
Connecting Israeli Defense Tech to US Needs
Log in

MedCu Technologies

Copper-oxide antimicrobial wound dressings (FDA/CE) for infection control in acute, chronic and burn wounds

Israel

Vitality Radar

65
Current
Industry
Updated 13 days ago

Pillar Analysis

Presence
Digital footprint, brand visibility, and online reach across channels
72
Business
Revenue signals, funding status, partnerships, and market traction
68
Innovation
R&D activity, patents, product launches, and technology adoption
86
Pulse
Recent momentum — hiring trends, news mentions, and social engagement
41
Capacity
Team strength, leadership depth, and organizational scale
58

Strategic Assessment

Strategic Vector

MedCu is positioned as a niche, science-led medtech company focused on copper-based antimicrobial wound care, with strong differentiation from its FDA/CE-cleared product positioning and patent-backed technology. Its trajectory appears to be commercialization-focused rather than broad platform expansion, with evidence of channel partnerships and external validation but limited visible scale signals.

Efficiency Ratio

The company appears to convert a relatively small team into a high-value regulatory and intellectual-property footprint, suggesting strong output efficiency for its size.

Evidence Signals

Certification HIGH CONF undated

Copper-based wound dressings are described as FDA-cleared and CE-cleared on MedCu and third-party profiles.

View source Israel
Other HIGH CONF undated

MedCu describes itself as the world’s first provider of wound dressing products impregnated with copper oxide microparticles.

View source Israel
Other MEDIUM CONF undated

Third-party sources state MedCu is protected by 30 patents worldwide.

View source Israel
Partnership HIGH CONF undated

MedTech Innovator and MTEC list MedCu as a member/company in their ecosystems, indicating validation and network access in medtech channels.

View source Israel
Funding MEDIUM CONF undated

PitchBook reports MedTech Innovator has invested in MedCu.

View source Israel
Award MEDIUM CONF undated

MedCu won an innovation award at a U.S. medtech summit.

View source United States
Other HIGH CONF undated

Company profiles estimate the workforce at roughly 10-50 employees, with PitchBook listing 12 employees and SignalHire estimating 11.

View source Herzliya, Israel

About
Israeli medical-device company (HQ Herzliya, Israel) — the first to gain FDA and CE clearance for copper-oxide-impregnated wound dressings. MedCu embeds copper-oxide microparticles into single-use dressings that provide broad-spectrum antimicrobial action (bacteria, fungi, viruses) while supporting tissue regeneration, used for diabetic/pressure/venous ulcers, surgical wounds and first/second-degree burns (FDA 510(k) K180643). Co-founded by Dr. Gadi Borkow. Defense relevance: wound-infection control for prolonged field care and burns — a support capability to the combat-casualty chain rather than a point-of-injury intervention. Primarily chronic/civilian wound care today.
Tags
#wounddressing #antimicrobial #copper #woundcare #infectioncontrol #burns #fda #ce #device #dualuse

Suggest an edit

Footer

Connecting Israeli Defense Tech to US Needs

Powered by Meschonomy

Terms Privacy Contact